Novavax, Inc. (NVAX)

Acerca de Novavax, Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Al 3 de noviembre de 2026, la acción de Novavax, Inc. (NVAX) subió con fuerza a $9.73, un alza de 2.15% (+$0.21) frente al cierre anterior. En la sesión, las acciones han operado entre $9.45 y $9.95. Eso ubica a NVAX cerca de la mitad de su rango de 52 semanas, de $6.20 a $13.39. Novavax, Inc. opera en el sector de biological products, (no diagnostic substances) y tiene una capitalización de mercado de aproximadamente $1.57 mil millones, con cerca de 1.93 millones de acciones negociadas.

Últimas noticias de NVAX

• Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in EuropeYahoo Finance· 29 oct, 9:15 a.m. ET
• Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseYahoo Finance· 29 oct, 9:00 a.m. ET
• Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026Yahoo Finance· 29 oct, 8:00 a.m. ETET
• Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher247wallst.com· 28 oct, 12:04 p.m. ET
• Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to KnowYahoo Finance· 26 oct, 4:45 p.m. ET
• What Novavax Doubters OverlookedYahoo Finance· 24 oct, 3:09 a.m. ET
• 3 small-cap stocks walking a fine lineYahoo Finance· 23 oct, 4:24 p.m. ET
• Is Novavax (NVAX) Fully Priced Relative To Its Sales Base?Yahoo Finance· 23 oct, 3:08 p.m. ET

Fuente: Yahoo Finance RSS · Actualizado el 3 de noviembre de 2026

¿Quieres titulares, alertas e investigación con IA de NVAX en un solo lugar? Crea una cuenta gratis →

• @GhostRazer Yeah that partner read tracks imo on $NVAX. Thursday is a checkpoint for me, not the promised land moment. If Sanofi or Pfizer show real progress, the rest of the partner list gets a lot more interesting fast.

  @BiotechSwings· 3 nov, 2:04 p.m. ET

• $NVAX Prevnar35 makes sense. Look at the adjuvants and the adjuvant free versions has twice the amount of antigen. Matrix M = antigen sparing, type of immune response th1 + th2 etc

  @UndSchwung· 3 nov, 2:00 p.m. ET

• Thanks for keeping me green in this red market. Made $5.2K profits :) Make sure you drop a Follow to @PremiumCollection below. He's been calling some insane runners 💯🥂 Will be loading more $NVAX $IREN $NBIS for swings

  @RagnirLothbrok· 3 nov, 1:58 p.m. ET· Alcista

• $NVAX I didn't see ERs or listen to the ECs for Pfiser or Sanofi but based on comments from other posters here it seems like they didn't shower us with love. Seems that Sanofi for sure and likely Pfiser too are the farthest along in researching potential projects with …

  @GhostRazer· 3 nov, 1:57 p.m. ET

• $NVAX 5 years of "Happy Talk" Jacobs. He's gotten fabulously wealthy and shareholders have gotten poor. And he keeps getting rewarded for poor execution and mismanagement.

  @BensonFuller· 3 nov, 1:10 p.m. ET

Fuente: Stocktwits. Las publicaciones de usuarios son opiniones, no hechos verificados. Ver lo que es tendencia →